Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 94.6% in January

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 144,200 shares, an increase of 94.6% from the December 31st total of 74,100 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average daily trading volume, of 55,400 shares, the days-to-cover ratio is currently 2.6 days.

Akari Therapeutics Stock Performance

Shares of NASDAQ:AKTX opened at $1.35 on Friday. The business has a 50 day simple moving average of $1.16 and a two-hundred day simple moving average of $2.43. Akari Therapeutics has a 1 year low of $0.90 and a 1 year high of $4.40.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a research note on Wednesday. They issued a “sell” rating on the stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.